{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes, Ian Chau, Mike Clarke, Annmarie Doran, Margaret Grayson, Danny McAuley, Cliona McDowell, Glenn Phair, Ruth Plummer, Dawn Storey, Anne Thomas, Richard Wilson & Ronan McMullan.

Vicky Coyle ^1,*, Caroline Forde ¹, Richard Adams ², Ashley Agus ³, Rosemary Barnes ⁴, Ian Chau ⁵, Mike Clarke ⁶, Annmarie Doran ³, Margaret Grayson ⁷, Danny McAuley ⁸, Cliona McDowell ³, Glenn Phair ³, Ruth Plummer ⁹, Dawn Storey ¹⁰, Anne Thomas ¹¹, Richard Wilson ¹², Ronan McMullan ⁸

¹ Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, UK
² Centre for Trials Research – Cancer Division, Cardiff University, Cardiff, UK
³ Northern Ireland Clinical Trials Unit, Belfast Health and Social Care Trust, Belfast, UK
⁴ School of Medicine, Cardiff University, Cardiff, UK
⁵ Department of Medicine, Royal Marsden Hospital, Surrey, UK
⁶ Centre for Public Health, Queens University Belfast, Belfast, UK
⁷ Northern Ireland Cancer Research Consumer Forum, Belfast Health and Social Care Trust, Belfast, UK
⁸ Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK
⁹ Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
¹⁰ The Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, UK
¹¹ Leicester Cancer Research Centre, University of Leicester, Leicester, UK
¹² Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
^* Corresponding author Email: v.coyle@qub.ac.uk

Disclosure of interests

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/RGTP7112.

Primary conflicts of interest: Vicky Coyle reports a Cancer Research UK Doctoral Fellowship research grant that part-supported this submitted work. She also reports research grants from Cancer Research UK and Astex Pharmaceuticals (UK) as well as personal fees and non-financial support from Servier Laboratories (France) for attending educational meetings, all unrelated to the submitted work. Richard Adams reports research grants from AstraZeneca PLC (UK) and Merck Sharp & Dohme Ltd (MSD, UK) as well as personal fees from Bayer Healthcare Pharmaceuticals LLC (Germany), Amgen Inc. (USA) and Servier Laboratories and non-financial support for attending meetings from Amgen Inc., Servier Laboratories and Merck Serono (Switzerland), all unrelated to the submitted work. Ashley Agus reports membership of the NIHRHTA Programme General Funding Committee. Ian Chau reports grants or contracts from Janssen-Cilag and Eli Lilly and Company. He also reports personal fees from Eli Lilly and Company (USA), AstraZeneca PLC, MSD, Merck Serono, Bristol Meyers Squibb Inc. (USA), Bayer Healthcare Pharmaceuticals LLC, Roche AG (Switzerland), OncXerna (China), Pierre Fabre Pharmaceuticals Inc. (France), Boehringer Ingelheim (Germany), Incyte Inc. (USA), Astellas Pharma (Japan), GlaxoSmithKline Ltd (UK), SOTIO (Czech Republic), Eisai (Japan), Five Prime Therapeutics, Inc. (USA), Symphogen (Denmark) and Servier Laboratories. Mike Clarke reports membership of the NIHR CRSU Funding Board, NIHRHTA Funding Teleconference Members, NIRH HTA Prioritisation Committee B Methods Group and NIHRHTA General Committee. Daniel McAuley reports research grants from NIHR, Innovate UK, Medical Research Council (MRC), Novavax Inc. (USA), the Northern Ireland HSC R&D Division, and the Wellcome Trust as well as personal fees from Bayer Healthcare Pharmaceuticals LLC, GlaxoSmithKline Ltd (UK), Boehringer Ingelheim (Germany), Novartis AG (Switzerland) and Eli Lilly and Company (USA); he also reports non-financial support for attending meetings from Vir Biotechnology Inc. (USA) and Faron Pharmaceuticals (Finland). He also reports spousal personal fees from Insmed, Inc. and the California Institute for Regenerative Medicine. Apart from NIHR funding for this trial, all others listed are unrelated to the submitted work. He is co-director of research for the Intensive Care Society (UK) and Programme Director of the NIHR/MRC Efficacy & Mechanisms Evaluation (EME) Programme. He also reports membership of the EME Strategy Advisory Committee, the EME Funding Committee, the EME Funding Committee Sub-Group: Remit and Competitiveness and former membership of the NIHR/UKRI COVID-19 reviewing committee and the HTA General Committee and Commissioning Committees. Ronan McMullan reports research grants from the NIHRHTA Programme, NIHR EME Programme, Wellcome Trust, NI Chest, Heart & Stroke Association and Randox Laboratories Ltd (UK), as well as personal fees and non-financial support for attending meetings from Gilead Sciences Europe Ltd (UK), all unrelated to the submitted work. He is also a member of the NIHRHTA Programme Prioritisation Committee B. Ruth Plummer reports membership of the NIHR EME Funding Committee. Caroline Forde, Rosemary Barnes, Annmarie Doran, Margaret Grayson, Cliona McDowell, Glenn Phair, Dawn Storey, Anne Thomas and Richard Wilson report no competing interests.